Hasil Pencarian - Roland B Walter

Perbaiki Hasil
  1. 1
    The present and future of measurable residual disease testing in acute myeloid leukemia

    The present and future of measurable residual disease testing in acute myeloid leukemia oleh James S. Blachly, Roland B. Walter, Christopher S. Hourigan

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Evaluating measurable residual disease in acute myeloid leukemia

    Evaluating measurable residual disease in acute myeloid leukemia oleh Farhad Ravandi, Roland B. Walter, Sylvie D. Freeman

    Diterbitkan 2018-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia

    Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia oleh Roland B. Walter, Bruno C. Medeiros, Bayard L. Powell, Charles A. Schiffer, Frederick R. Appelbaum, Elihu H. Estey

    Diterbitkan 2012-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization.

    Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. oleh Eva Jager, Vincent H J van der Velden, Jeroen G te Marvelde, Roland B Walter, Zvia Agur, Vladimir Vainstein

    Diterbitkan 2011-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330

    Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330 oleh George S. Laszlo, Mary E. Beddoe, Colin D. Godwin, Olivia M. Bates, Chelsea J. Gudgeon, Kimberly H. Harrington, Roland B. Walter

    Diterbitkan 2019-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study

    Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study oleh Roland B. Walter, Stephanie J. Lee, Kelda M. Gardner, Xiaoyu Chai, Kathleen Shannon-Dorcy, Frederick R. Appelbaum, Elihu H. Estey

    Diterbitkan 2011-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia

    Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia oleh Daisuke Araki, Megan Othus, Roland B. Walter, Vicky Sandhu, Brenda M. Sandmaier, Pamela S. Becker, Frederick R. Appelbaum, Elihu H. Estey

    Diterbitkan 2015-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia

    Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia oleh Wei-Gang Tong, Vicky K. Sandhu, Brent L. Wood, Paul C. Hendrie, Pamela S. Becker, John M. Pagel, Roland B. Walter, Elihu H. Estey

    Diterbitkan 2015-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study

    Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study oleh Roland B. Walter, Bruno C. Medeiros, Kelda M. Gardner, Kaysey F. Orlowski, Leonel Gallegos, Bart L. Scott, Paul C. Hendrie, Elihu H. Estey

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia

    Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute... oleh Corentin Orvain, Jacob A. Wilson, Min Fang, Brenda M. Sandmaier, Eduardo Rodríguez-Arbolí, Brent L. Wood, Megan Othus, Frederick R. Appelbaum, Roland B. Walter

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.

    The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk. oleh Kimberly H Harrington, Chelsea J Gudgeon, George S Laszlo, Kathryn J Newhall, Angus M Sinclair, Stanley R Frankel, Roman Kischel, Guang Chen, Roland B Walter

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia

    Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia oleh Raffaele Palmieri, Megan Othus, Guang-Shing Cheng, Francesco Buccisano, Giovangiacinto Paterno, Luca Maurillo, Maria Ilaria Del Principe, Giuseppe Sconocchia, Adriano Venditti, Roland B. Walter

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates

    Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates oleh Nicholas E. Petty, Stefan Radtke, Emily Fields, Olivier Humbert, Mallory J. Llewellyn, George S. Laszlo, Haiying Zhu, Keith R. Jerome, Roland B. Walter, Hans-Peter Kiem

    Diterbitkan 2023-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Time independent factors that predict relapse in adults with acute myeloid leukemia

    Time independent factors that predict relapse in adults with acute myeloid leukemia oleh John J. Lim, Megan Othus, Carole M. Shaw, Kathryn Russell, Anna B. Halpern, Jacob S. Appelbaum, Paul Hendrie, Roland B. Walter, Elihu H. Estey, Mary-Elizabeth M. Percival

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG

    Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG oleh Roland B. Walter, Megan Othus, Bob Löwenberg, Gert J. Ossenkoppele, Stephen H. Petersdorf, Thomas Pabst, Marie-Christiane Vekemans, Frederick R. Appelbaum, Harry P. Erba, Elihu H. Estey

    Diterbitkan 2015-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility

    Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility oleh Mary-Elizabeth M. Percival, Megan Othus, Sarah Mirahsani, Kelda M. Gardner, Carole Shaw, Anna B. Halpern, Pamela S. Becker, Paul C. Hendrie, Mohamed L. Sorror, Roland B. Walter, Elihu H. Estey

    Diterbitkan 2020-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

    Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell tra... oleh Eduardo Rodríguez-Arbolí, Megan Othus, Corentin Orvain, Lucas C. Zarling, Brenda M. Sandmaier, Filippo Milano, Gary Schoch, Chris Davis, H. Joachim Deeg, Frederick R. Appelbaum, Rainer Storb, Roland B. Walter

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.

    AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. oleh David B Rosen, Kimberly H Harrington, James A Cordeiro, Ling Y Leung, Santosh Putta, Norman Lacayo, George S Laszlo, Chelsea J Gudgeon, Donna E Hogge, Rachael E Hawtin, Alessandra Cesano, Roland B Walter

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm

    Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm oleh Roland B. Walter, Megan Othus, Kaysey F. Orlowski, Emily N. McDaniel, Bart L. Scott, Pamela S. Becker, Mary-Elizabeth M. Percival, Paul C. Hendrie, Bruno C. Medeiros, Michael T. Chiarella, Arthur C. Louie, Elihu H. Estey

    Diterbitkan 2018-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group

    Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the C... oleh George S. Laszlo, Todd A. Alonzo, Chelsea J. Gudgeon, Kimberly H. Harrington, Alex Kentsis, Robert B. Gerbing, Yi-Cheng Wang, Rhonda E. Ries, Susana C. Raimondi, Betsy A. Hirsch, Alan S. Gamis, Soheil Meshinchi, Roland B. Walter

    Diterbitkan 2016-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: